Question 1

How many shares of BTAI does UBS Group AG own?

Accepted Answer

As of 2026-Q2, UBS Group AG holds 158,065 shares of BTAI (BIOXCEL THERAPEUTICS INC).

Question 2

What is UBS Group AG's BTAI position worth?

Accepted Answer

As of 2026-Q2, UBS Group AG's BTAI position is worth $222,871.

Question 3

Is UBS Group AG buying or selling BTAI?

Accepted Answer

In 2026-Q2, UBS Group AG increased their BTAI position (+199.4% change in shares).

Question 4

When did UBS Group AG first buy BTAI?

Accepted Answer

Based on available 13F filings, UBS Group AG first reported a position in BTAI in 2024-Q3. They have held the position across 30 quarters.

Quarter	Action	Shares	Change	Value	Weight	Price	Conviction
2026-Q2 Latest	Increased	158,065	+199.4%	$222,871	0.0%	$1.41	25
2026-Q1	Increased	52,788	+37.7%	$70,736	0.0%	$1.60	19
2025-Q4	Decreased	38,340	-11.9%	$61,344	0.0%	$1.53	0
2025-Q3	Increased	43,542	+9.2%	$111,468	0.0%	$2.62	16
2025-Q2	Decreased	39,882	-60.8%	$72,187	0.0%	$1.77	0
2025-Q1	Decreased	101,778	-92.0%	$206,609	0.0%	$2.12	0
2024-Q4	Increased	1.3M	+9553.0%	$477,558	0.0%	$5.87	39
2024-Q3	Decreased	13,228	-74.8%	$8,069	0.0%	$9.65	0